Fulminant Crohn's colitis: when only an antibody will do

Area of Science:

• Gastroenterology
• Immunology
• Colorectal Surgery

Background:

• Fulminant Crohn's colitis with toxic megacolon typically necessitates surgical intervention.
• Surgery for this condition is associated with significant morbidity and mortality risks.

Observation:

• A case study involving a female patient with steroid-refractory fulminant Crohn's colitis and toxic megacolon was presented.
• The patient received treatment with adalimumab, a monoclonal antibody targeting tumor necrosis factor.

Findings:

• Adalimumab treatment led to a rapid clinical response and remission in the patient.
• This therapeutic approach successfully averted the need for emergency colectomy.

Implications:

• This represents the first documented use of an antitumor necrosis factor antibody for fulminant Crohn's colitis.
• Adalimumab is demonstrated as a viable treatment option for fulminant colitis, regardless of underlying cause.
• This case highlights a potential non-surgical management strategy for severe ulcerative colitis, reducing surgical risks.